Cullinan Therapeutics Quote - CGEM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

10.91

Bid

10.90

Offer

11.85

Volume

665,179

10.50 Day's Range 11.89

9.5005 52 Week Range 30.1886

Market Cap

635.263M

Previous Close

10.45

Open

10.82

Last Trade

11.69

Last Trade Time

Financial Volume

US$ 7,495,962

VWAP

11.2691

Average Volume (3m)

569,216

Shares Outstanding

58,227,593

Dividend Yield

PE Ratio

-4.28

Earnings Per Share (EPS)

-2.63

Revenue

Net Profit

-153.16M

Cullinan Oncology Inc is a biopharmaceutical company. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. Cullinan Oncology Inc is a biopharmaceutical company. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients.

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.cullinantherapeutics.com

Headquarters

Wilmington, Delaware, USA

Founded

Cullinan Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker CGEM. The last closing price for Cullinan Therapeutics was US$10.45. Over the last year, Cullinan Therapeutics shares have traded in a share price range of US$ 9.5005 to US$ 30.1886.

Cullinan Therapeutics currently has 58,227,593 shares in issue. The market capitalisation of Cullinan Therapeutics is US$608.48 million. Cullinan Therapeutics has a price to earnings ratio (PE ratio) of -4.28.

Form 8-K - Current report

Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy

Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024

Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune diseases Cullinan will share details of global...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.51	4.90384615385	10.4	11.25	10.1101	400544	10.47282763	CS
4	-1.83	-14.3642072214	12.74	12.985	9.5005	501201	10.84944269	CS
12	-5.58	-33.8386901152	16.49	17.5034	9.5005	569216	12.61706643	CS
26	-9.27	-45.9365708622	20.18	20.365	9.5005	553723	15.23390851	CS
52	-2.22	-16.9078446306	13.13	30.1886	9.5005	658837	18.07087171	CS
156	-1.81	-14.2295597484	12.72	30.1886	7.3	387428	15.05655654	CS
260	-31.09	-74.0238095238	42	59.85	7.3	355425	17.70786236	CS

CGEM - Frequently Asked Questions (FAQ)

What is the current Cullinan Therapeutics share price?

The current share price of Cullinan Therapeutics is US$ 10.91

How many Cullinan Therapeutics shares are in issue?

Cullinan Therapeutics has 58,227,593 shares in issue

What is the market cap of Cullinan Therapeutics?

The market capitalisation of Cullinan Therapeutics is USD 608.48M

What is the 1 year trading range for Cullinan Therapeutics share price?

Cullinan Therapeutics has traded in the range of US$ 9.5005 to US$ 30.1886 during the past year

What is the PE ratio of Cullinan Therapeutics?

The price to earnings ratio of Cullinan Therapeutics is -4.28

What is the reporting currency for Cullinan Therapeutics?

Cullinan Therapeutics reports financial results in USD

What is the latest annual profit for Cullinan Therapeutics?

The latest annual profit of Cullinan Therapeutics is USD -153.16M

What is the registered address of Cullinan Therapeutics?

The registered address for Cullinan Therapeutics is CORPORATION TRUST CENTER, 1209 ORANGE STREET, NEW CASTLE, WILMINGTON, DELAWARE, 19801

What is the Cullinan Therapeutics website address?

The website address for Cullinan Therapeutics is www.cullinantherapeutics.com

Which industry sector does Cullinan Therapeutics operate in?

Cullinan Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
DGNXDiginex Ltd	US$ 49.18 (228.09%)	3.34M
SLXNSilexion Therapeutics Corporation	US$ 3.1301 (131.86%)	330.45M
KRKR36Kr Holdings Inc	US$ 9.10 (114.12%)	23.61M
SPGCSacks Parente Golf Inc	US$ 0.6001 (57.92%)	52.17M
XFORX4 Pharmaceuticals Inc	US$ 0.7542 (56.54%)	42.5M
ZKINZK International Group Co Ltd	US$ 0.4813 (-41.21%)	3.1M
MGOLMGO Global Inc	US$ 0.1019 (-38.73%)	70.52M
BACKIMAC Holdings Inc	US$ 0.7869 (-35.50%)	2.37M
EYENEyenovia Inc	US$ 0.03695 (-35.18%)	25.31M
HAOHaoxi Health Technology Ltd	US$ 2.52 (-31.89%)	484.94k
NVDANVIDIA Corporation	US$ 123.70 (-4.10%)	466.94M
SLXNSilexion Therapeutics Corporation	US$ 3.1301 (131.86%)	330.45M
OCEAOcean Biomedical Inc	US$ 0.249929 (-24.26%)	186.52M
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.428 (-6.98%)	148.12M
RIMEAlgorhythm Holdings Inc	US$ 0.0259 (-16.18%)	138.96M